Arrowhead Pharmaceuticals Inc share price logo

Arrowhead Pharmaceuticals Inc

NASDAQ: ARWR

Large Cap

$79.03

+1.29

(+1.66%)

as on

Arrowhead Pharmaceuticals Inc Stock Performance

as on May 13, 2026 at 6:59 am IST

  • Day's Low

    Day's High

    $76.62
    $79.67
    downward going graph

    3.05%

    Downside

    0.81%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $13.42
    $80.27
    downward going graph

    83.02%

    Downside

    1.56%

    Upside

    downward going graph

Arrowhead Pharmaceuticals Inc share price movements today

Previous Close
$77.74
Open
$76.88
Volume
1.2M
Day's Low - High
$76.62 - $79.67
52 Week Low - High
$13.42 - $80.27

Arrowhead Pharmaceuticals Inc Historical Returns

1 Month Return
+ 19.34 %
3 Month Return
+ 24.62 %
1 Year Return
+ 456.48 %
3 Year Return
+ 97.71 %
5 Year Return
+ 13.16 %

Arrowhead Pharmaceuticals Inc Stock Fundamentals & Key Indicators

Check Arrowhead Pharmaceuticals Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$11.0B

EPS (TTM)

-3.2189

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.10%

PE Ratio (TTM)

0

PEG Ratio

-1.32

EBITDA

-196.5M

Revenue (TTM)

622.0M

Profit Margin

-48.38%

Return On Equity TTM

-42.37%

Arrowhead Pharmaceuticals Inc vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Arrowhead Pharmaceuticals Inc with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
BUY$11.0B13.16%NA-48.38%
BUY$39.4B113.59%74.1312.55%
NA$32.2BNA70.468.94%
BUY$109.1B104.61%25.5135.51%
BUY$74.9B40.55%17.4529.65%

Stock Returns calculator for Arrowhead Pharmaceuticals Inc Stock including INR - Dollar returns

The Arrowhead Pharmaceuticals Inc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Arrowhead Pharmaceuticals Inc investment value today

Current value as on today

₹6,37,246

Returns

₹5,37,246

(+537.25%)

Returns from Arrowhead Pharmaceuticals Inc Stock

₹4,65,712 (+465.71%)

Dollar Impact

₹71,533 (+71.53%)

Analyst Recommendation on Arrowhead Pharmaceuticals Inc Stock

Based on 20 analysts

BUY

75.00%

Buy

25.00%

Hold

0.00%

Sell

Based on 20 analysts, 75% of analysts recommend a 'BUY' rating for Arrowhead Pharmaceuticals Inc. Average target price of $86.67

Arrowhead Pharmaceuticals Inc Share Price Target

Get share price movements and forecasts by analysts on Arrowhead Pharmaceuticals Inc.

What analysts predicted

8.82%UPSIDE

Target Price

$86.67

Current Price

$79.03

Analyzed by

20 Analysts

Target

$86.67

Arrowhead Pharmaceuticals Inc target price $86.67, a slight upside of 8.82% compared to current price of $79.03. According to 20 analysts rating.

Indian Investors' Interest in Arrowhead Pharmaceuticals Inc Stock

Search interest for Arrowhead Pharmaceuticals Inc Stock has increased by 105% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:105% versus previous 30 day period

Arrowhead Pharmaceuticals Inc Quarterly Profit & Loss

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Total Revenue
3
-
-
23
2
542
27
256
264
73
Gross Profit
0
-4
-4
-5
-2
536
27
256
264
67
Operating Income
-136
-126
-176
-162
-161
381
-165
44
40
-141
EBITDA
-129
-115
-164
-153
-148
397
-148
64
57
-141
Interest Expense
5
7
5
14
21
21
24
21
22
23
Depreciation
4
4
4
5
5
6
6
6
6
-
Income Before Tax
-138
-126
-173
-172
-175
369
-179
36
28
-137
Income Tax Expense
-3
-1
-3
0
0
1
0
20
0
0
Net Income
-132
-125
-170
-170
-173
370
-175
-23
30
-132
Net Profit Margin
-3741.59%
0.00%
0.00%
-722.95%
-6923.40%
68.26%
-631.11%
-9.26%
11.67%
-180.01%

Arrowhead Pharmaceuticals Inc Annual Profit & Loss

All numbers in Millions USD

Sep 2016
Sep 2017
Sep 2018
Sep 2019
Sep 2020
Sep 2021
Sep 2022
Sep 2023
Sep 2024
Sep 2025
Total Revenue
0
31
16
168
87
138
243
240
3
829
Gross Profit
0
31
16
168
87
138
243
228
-15
829
Operating Income
-81
-36
-55
61
-93
-149
-178
-205
-601
98
EBITDA
-76
-32
-51
65
-87
-132
-168
-175
-561
164
Interest Expense
265
415
1,048
6,957
9,190
6
5
18
32
89
Depreciation
-
4
4
4
5
8
10
12
18
23
Income Before Tax
-81
-34
-54
68
-84
-140
-172
-206
-612
51
Income Tax Expense
0
0
0
0
0
0
3
2
-2
21
Net Income
-81
-34
-54
67
-84
-140
-176
-205
-599
-1
Net Profit Margin
-51614.63%
-109.46%
-337.32%
40.27%
-96.09%
-101.85%
-72.56%
-85.27%
-16882.37%
-0.20%

Arrowhead Pharmaceuticals Inc Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Net Income
-126
-173
-173
-175
367
-178
16
28
-132
Operating Cash Flow
-92
-115
-137
-146
460
-154
20
13
84
Investing Cash Flow
-268
6
-222
76
-420
141
72
-23
-894
Financing Cash Flow
430
50
389
20
92
-42
3
-14
795
Change in Cash
69
-58
33
-48
131
-55
96
-24
-13

Arrowhead Pharmaceuticals Inc Annual Cash Flow

All numbers in Millions USD

Sep 2017
Sep 2018
Sep 2019
Sep 2020
Sep 2021
Sep 2022
Sep 2023
Sep 2024
Sep 2025
Net Income
-34
-54
67
-84
-140
-176
-209
-609
30
Operating Cash Flow
-23
-47
173
-95
171
-136
-153
-462
179
Investing Cash Flow
-48
-7
-47
-240
-141
-5
-96
-420
-129
Financing Cash Flow
12
59
66
257
11
65
253
870
74
Change in Cash
-60
5
191
-78
40
-76
2
-8
123

Global Institutional Holdings in Arrowhead Pharmaceuticals Inc

Funds
Holdings
BlackRock Inc
15.52%
State Street Corp
4.66%
Fred Alger Management, LLC
1.33%
Goldman Sachs Group Inc
1.53%
Charles Schwab Investment Management Inc
0.99%

Arrowhead Pharmaceuticals Inc News & Key Events

  • img

    Today's Timeline - 21 April

    Tue, 07:33 PM

    -

    Morgan Stanley upgrades Arrowhead to Overweight, raising price target to $100, citing strong momentum ahead of Phase 3 data.

Insights on Arrowhead Pharmaceuticals Inc

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Best in 3 Years

    img

    In the last 3 years, ARWR has outperformed top 5 stocks with highest market-cap in its industry

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 6 months, ARWR stock has moved up by 89.0%

  • imgPOSITIVE IMPACT

    Best in 1 Year

    img

    In the last 1 year, ARWR has outperformed top 5 stocks with highest market-cap in its industry

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 2 quarters, 30.81M → -132.73M (in $), with an average decrease of 530.8% per quarter

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Revenue is down for the last 2 quarters, 264.03M → 73.73M (in $), with an average decrease of 72.1% per quarter

About Arrowhead Pharmaceuticals Inc

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California.
OrganisationArrowhead Pharmaceuticals Inc
Headquarters177 East Colorado Boulevard, Pasadena, CA, United States, 91105
IndustryBiotechnology
CEODr. Christopher R. Anzalone Ph.D.
E-voting on sharesClick here to vote

Key Management of Arrowhead Pharmaceuticals Inc

Name

Title

Dr. James C. Hamilton M.D., MBA

Chief Medical Officer and Head of R&D

Dr. Mark M. Davis Ph.D.

Founder and Founder & Director of Insert Therapeutics Inc & Calando

Dr. Vincent Anzalone CFA

Head of Investor Relations & VP

Mr. Howard Lovy

Director of Communications

Aaron Tan

Head of Tax

Dr. Christopher R. Anzalone Ph.D.

Chairman, CEO & President

Mr. Daniel J. Apel

Chief Financial Officer

Dr. Mark Seefeld

Head of Toxicology & VP

Dr. Tao Pei Ph.D.

Chief Scientific Officer

Dr. Bruce D. Given M.D.

Chief Medical Scientist

FAQs

What is Arrowhead Pharmaceuticals Inc share price today?

Arrowhead Pharmaceuticals Inc share price today is $79.03 as on at the close of the market. Arrowhead Pharmaceuticals Inc share today touched a day high of $79.67 and a low of $76.62.

What is the 52 week high and 52 week low for Arrowhead Pharmaceuticals Inc share?

Arrowhead Pharmaceuticals Inc share touched a 52 week high of $80.27 on and a 52 week low of $13.42 on . Arrowhead Pharmaceuticals Inc stock price today i.e. is closed at $79.03,which is 1.54% down from its 52 week high and 488.90% up from its 52 week low.

What is Arrowhead Pharmaceuticals Inc's market capitalisation today?

Arrowhead Pharmaceuticals Inc market capitalisation is $0.01T as on .

How to invest in Arrowhead Pharmaceuticals Inc Stock (ARWR) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Arrowhead Pharmaceuticals Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Arrowhead Pharmaceuticals Inc Shares that will get you 0.0190 shares as per Arrowhead Pharmaceuticals Inc share price of $79.03 per share as on May 13, 2026 at 1:29 am IST.

What is the minimum amount required to buy Arrowhead Pharmaceuticals Inc Stock (ARWR) from India?

Indian investors can start investing in Arrowhead Pharmaceuticals Inc (ARWR) shares with as little as ₹95.618 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹956.18 in Arrowhead Pharmaceuticals Inc stock (as per the Rupee-Dollar exchange rate as on ). Based on Arrowhead Pharmaceuticals Inc share’s latest price of $79.03 as on May 13, 2026 at 1:29 am IST, you will get 0.1265 shares of Arrowhead Pharmaceuticals Inc. Learn more about fractional shares .

What are the returns that Arrowhead Pharmaceuticals Inc has given to Indian investors in the last 5 years?

Arrowhead Pharmaceuticals Inc stock has given 13.16% share price returns and 29.61% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?